Recombinant Plasma Protein Therapeutics Market Size - Global Industry, Share, Analysis, Trends and Forecast 2024 - 2032
CHAPTER 1. Industry Overview of Recombinant Plasma Protein Therapeutics Market
1.1. Definition and Scope
1.1.1. Definition of Recombinant Plasma Protein Therapeutics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Recombinant Plasma Protein Therapeutics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Recombinant Plasma Protein Therapeutics Market By Drug Class
1.2.3. Recombinant Plasma Protein Therapeutics Market By Cell Line
1.2.4. Recombinant Plasma Protein Therapeutics Market By Indication
1.2.5. Recombinant Plasma Protein Therapeutics Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.1.3. Driver 3
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.2.3. Restraint 3
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.3.3. Opportunity 3
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Recombinant Plasma Protein Therapeutics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Recombinant Plasma Protein Therapeutics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2023
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2023
4.2. R&D Status of Major Manufacturers in 2023
CHAPTER 5. Recombinant Plasma Protein Therapeutics Market By Drug Class
5.1. Introduction
5.2. Recombinant Plasma Protein Therapeutics Revenue By Drug Class
5.2.1. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast, By Drug Class, 2020-2032
5.2.2. Recombinant Coagulation Factors
5.2.2.1. Recombinant Coagulation Factors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2. Recombinant Coagulation Factor VIII
5.2.2.2.1. Recombinant Coagulation Factor VIII Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3. Recombinant Coagulation Factor IX
5.2.2.3.1. Recombinant Coagulation Factor IX Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.4. Recombinant Coagulation Factor VIIa
5.2.2.4.1. Recombinant Coagulation Factor VIIa Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.5. Others
5.2.2.5.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Human C1 Esterase Inhibitor
5.2.3.1. Human C1 Esterase Inhibitor Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Recombinant Plasma Protein Therapeutics Market By Cell Line
6.1. Introduction
6.2. Recombinant Plasma Protein Therapeutics Revenue By Cell Line
6.2.1. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast, By Cell Line, 2020-2032
6.2.2. Chinese Hamster Ovary (CHO) Cell Line
6.2.2.1. Chinese Hamster Ovary (CHO) Cell Line Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Baby Hamster Kidney (BHK) Cell Line
6.2.3.1. Baby Hamster Kidney (BHK) Cell Line Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. Recombinant Plasma Protein Therapeutics Market By Indication
7.1. Introduction
7.2. Recombinant Plasma Protein Therapeutics Revenue By Indication
7.2.1. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast, By Indication, 2020-2032
7.2.2. Hemophilia A
7.2.2.1. Hemophilia A Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.3. Hemophilia B
7.2.3.1. Hemophilia B Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.4. Von Willebrand Disease
7.2.4.1. Von Willebrand Disease Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.5. Others
7.2.5.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Recombinant Plasma Protein Therapeutics Market By Country
8.1. North America Recombinant Plasma Protein Therapeutics Market Overview
8.2. U.S.
8.2.1. U.S. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.2.2. U.S. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
8.2.3. U.S. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
8.3. Canada
8.3.1. Canada Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.3.2. Canada Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
8.3.3. Canada Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Recombinant Plasma Protein Therapeutics Market By Country
9.1. Europe Recombinant Plasma Protein Therapeutics Market Overview
9.2. U.K.
9.2.1. U.K. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.2.2. U.K. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
9.2.3. U.K. Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
9.3. Germany
9.3.1. Germany Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.3.2. Germany Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
9.3.3. Germany Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
9.4. France
9.4.1. France Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.4.2. France Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
9.4.3. France Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
9.5. Spain
9.5.1. Spain Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.5.2. Spain Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
9.5.3. Spain Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.6.2. Rest of Europe Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
9.6.3. Rest of Europe Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Recombinant Plasma Protein Therapeutics Market By Country
10.1. Asia Pacific Recombinant Plasma Protein Therapeutics Market Overview
10.2. China
10.2.1. China Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.2.2. China Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
10.2.3. China Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
10.3. Japan
10.3.1. Japan Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.3.2. Japan Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
10.3.3. Japan Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
10.4. India
10.4.1. India Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.4.2. India Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
10.4.3. India Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
10.5. Australia
10.5.1. Australia Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.5.2. Australia Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
10.5.3. Australia Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
10.6. South Korea
10.6.1. South Korea Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.6.2. South Korea Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
10.6.3. South Korea Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.7.2. Rest of Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
10.7.3. Rest of Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Recombinant Plasma Protein Therapeutics Market By Country
11.1. Latin America Recombinant Plasma Protein Therapeutics Market Overview
11.2. Brazil
11.2.1. Brazil Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.2.2. Brazil Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
11.2.3. Brazil Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
11.3. Mexico
11.3.1. Mexico Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.3.2. Mexico Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
11.3.3. Mexico Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Latin America Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
11.4.3. Rest of Latin America Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Recombinant Plasma Protein Therapeutics Market By Country
12.1. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Overview
12.2. GCC
12.2.1. GCC Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.2.2. GCC Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
12.2.3. GCC Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
12.3. South Africa
12.3.1. South Africa Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.3.2. South Africa Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
12.3.3. South Africa Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.4.2. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Cell Line, 2020-2032
12.4.3. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue (USD Million) and Forecast By Indication, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Recombinant Plasma Protein Therapeutics Market
13.1. Recombinant Plasma Protein Therapeutics Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and New Product Enhancements
13.2.3. Mergers And Acquisition In Global Recombinant Plasma Protein Therapeutics Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Octapharma
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Million), 2023
14.1.3.2. Octapharma 2023 Recombinant Plasma Protein Therapeutics Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Takeda Pharmaceutical Company Limited
14.3. Pfizer Inc.
14.4. Ferring B.V.
14.5. Bayer AG
14.6. CSL Limited
14.7. Aptevo Therapeutics
14.8. Pharma Group NV
14.9. Sanofi
14.10. Novo Nordisk A / S
Frequently Asked Questions
How big is the recombinant plasma protein therapeutics market?
The recombinant plasma protein therapeutics market size was valued at USD 14.7 billion in 2023.
What is the CAGR of the global recombinant plasma protein therapeutics market from 2024 to 2032?
The CAGR of recombinant plasma protein therapeutics is 5.3% during the analysis period of 2024 to 2032.
Which are the key players in the recombinant plasma protein therapeutics market?
The key players operating in the global market are including Octapharma, Takeda Pharmaceutical Company Limited, Pfizer Inc., Ferring B.V., Bayer AG, CSL Limited, Aptevo Therapeutics, Pharma Group NV, Sanofi, and Novo Nordisk A / S.
Which region dominated the global recombinant plasma protein therapeutics market share?
North America held the dominating position in recombinant plasma protein therapeutics industry during the analysis period of 2024 to 2032.
Which region registered fastest CAGR from 2024 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of recombinant plasma protein therapeutics during the analysis period of 2024 to 2032.
What are the current trends and dynamics in the global recombinant plasma protein therapeutics industry?
The current trends and dynamics in the recombinant plasma protein therapeutics industry include increasing prevalence of hemophilia and other bleeding disorders, rising advancements in recombinant DNA technology, and growing preference for safer, non-plasma-derived therapeutics.
Which drug class held the maximum share in 2023?
The recombinant coagulation factors drug class held the maximum share of the recombinant plasma protein therapeutics industry. 
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
